Paclitaxel-based therapy no better than cisplatin and 5-FU for operable esophageal cancer

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷 / 1期
关键词：
D O I：
10.1038/ncponc0992
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7 / 8
页数：1
相关论文
共 50 条
  • [21] Comparison of neoadjuvant chemoradiation with carboplatin/paclitaxel or CDDP/5-FU for esophageal SCC
    Muench, S.
    Pigorsch, S.
    Feith, M.
    Slotta-Huspenina, J.
    Weichert, W.
    Friess, H.
    Combs, S.
    Habermehl, D.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S768 - S769
  • [22] Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer
    Al-Jumayli, Mohammed
    Choucair, Khalil
    Al-Obaidi, Ammar
    Park, Robin
    Bansal, Ajay
    Baranda, Joaquina
    Sun, Weijing
    Saeed, Anwaar
    ANTICANCER RESEARCH, 2022, 42 (01) : 59 - 66
  • [23] Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma
    Kaur, T.
    Khanduja, K. L.
    Gupta, R.
    Gupta, N. M.
    Vaiphei, K.
    DISEASES OF THE ESOPHAGUS, 2008, 21 (02): : 103 - 107
  • [24] Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Wing-Lok Chan
    Cheuk-Wai Choi
    Ian Yu-Hong Wong
    Terence Hon-Ting Tsang
    Adrian Tin-Chung Lam
    Rosa Pui-Ying Tse
    K. K. Chan
    Claudia Wong
    Betty Tze-Ting Law
    Emina Edith Cheung
    Siu-Yin Chan
    Ka-On Lam
    Dora Kwong
    Simon Law
    Annals of Surgical Oncology, 2023, 30 : 861 - 870
  • [25] Phase I Study of Definitive Chemoradiation With Cisplatin/5-FU Plus Cetuximab in Unresectable Esophageal Cancer
    Rades, D.
    Moehler, M. H.
    Schmidberger, H.
    Fellermann, K.
    Buerk, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S450 - S450
  • [26] Future directions of paclitaxel-based therapy of breast cancer
    Gianni, L
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 91 - 96
  • [27] Inhibition of PARP by hyperthermia or pharmacological inhibitors synergize with cisplatin and doxorubicin but not with 5-FU or paclitaxel
    Schaal, Lea
    Ulmer, Christoph
    Steurer, Wolfgang
    Muerdter, Thomas E.
    Aulitzky, Walter E.
    van der Kuip, Heiko
    CANCER RESEARCH, 2015, 75
  • [28] Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer
    Boggs, D. H.
    Tarabolous, C.
    Morris, C. G.
    Hanna, A.
    Burrows, W.
    Horiba, N.
    Suntharalingam, M.
    DISEASES OF THE ESOPHAGUS, 2015, 28 (07) : 619 - 625
  • [29] Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
    Cui Chen
    Feng-hua Wang
    Xin An
    Hui-yan Luo
    Zhi-qiang Wang
    Ying Liang
    Le Zhang
    Yu-hong Li
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 371 - 378
  • [30] Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
    Chen, Cui
    Wang, Feng-hua
    An, Xin
    Luo, Hui-yan
    Wang, Zhi-qiang
    Liang, Ying
    Zhang, Le
    Li, Yu-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 371 - 378
12345